The defendants in a shareholder class action over QRxPharma’s alleged failure to disclose problems with regulatory approval for its painkiller Moxduo have won access to information on class members’ financial brokers.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au